Compared to sclerostin, Dkk1, as an alternative Wnt inhibitor, has been less extensively studied with bone metabolism markers and bone histomorphometric parameters in patients with CKD-MBD [140,147,148]. The gene discussed is SOST; the disease is Marchiafava-Bignami disease.